Friday, February 14, 2020
9:59 AM EST – Fennec Pharmaceuticals Inc. : Reported its business update and financial results for the fiscal year ended December 31, 2019. Cash and cash equivalents were $13.7 million as of December 31, 2019. The reduction in cash balance over the fiscal year is the result of cash used for operating activities including regulatory expenses associated with the regulatory submissions of PEDMARK and expenses associated with commercial launch preparation. Net losses for the fourth quarter and year ended December 31, 2019 of $3.6 million ($0.18 per share) and $12.8 million ($0.64 per share), respectively, compared to $3.0 million ($0.15 per share) and $9.9 million ($0.52 per share), respectively, for the same periods in 2018. Fennec Pharmaceuticals Inc.
(T.FRX) shares were down $0.70 at 9.32.
Stocks in Play: Fennec Pharmaceuticals Inc., Fri, 14 Feb 2020 10:12:59 EST